PRINCIPIA BIOPHARMA INC.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$2.5M
Doctors Paid
7
Transactions
262
2021 Total
$1.8M
Payment Breakdown by Category
Research$2.5M (99.7%)
Consulting$6,350 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 255 | 99.7% |
| Consulting Fee | $6,350 | 7 | 0.3% |
Payments by Type
Research
$2.5M
255 transactions
General
$6,350
7 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease | $923,173 | 2 | 23 |
| A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP) | $273,250 | 0 | 51 |
| Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) | $243,220 | 0 | 41 |
| POP - hepatic insuf.- po | $167,123 | 0 | 9 |
| An Open-Label, Phase 1 Study to Evaluate the Effect of Mild and Moderate HepaticImpairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008) | $165,006 | 0 | 18 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus | $161,360 | 1 | 64 |
| Eff - ITP - po | $161,002 | 0 | 2 |
| PRN1008 - 015 - Healthy Male Subjects (ADME Study) | $150,079 | 0 | 3 |
| An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenia | $69,718 | 2 | 19 |
| Dose Find - "An Adaptive" - ITP - po | $67,448 | 3 | 5 |
| A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With Metastatic Urothelial Carcinoma With FGFR 1, 2, 3, or 4 Genetic Alterations | $38,506 | 0 | 7 |
| A Randomized Double-Blind Placebo-Controlled Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus | $23,914 | 0 | 8 |
| Eff - PV Pegasus - po | $16,439 | 0 | 5 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Rheumatology | $155,378 | 2 | $77,689 |
| Dermatology | $17,575 | 4 | $4,394 |
| Internal Medicine | $1,600 | 1 | $1,600 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Jack Bukowski, Md Phd, MD PHD | Rheumatology | Boston, MA | $145,065 | $0 |
| Gary Hoffman, M.d, M.D | Rheumatology | Cleveland, OH | $10,313 | $0 |
| Dr. Jeffrey Callen, M.d, M.D | Dermatology | Louisville, KY | $9,875 | $0 |
| Victoria Werth, Md, MD | Dermatology | Philadelphia, PA | $3,900 | $0 |
| Emma Guttman, Md, MD | Dermatology | New York, NY | $2,450 | $0 |
| Dr. David Kuter, Md Dphil, MD DPHIL | Internal Medicine | Boston, MA | $1,600 | $0 |
| Dr. Benjamin Chong, M.d, M.D | Dermatology | Dallas, TX | $1,350 | $0 |
Ad
Payment Categories
- Consulting $6,350
- Research $2.5M
About PRINCIPIA BIOPHARMA INC.
PRINCIPIA BIOPHARMA INC. has made $2.5M in payments to 7 healthcare providers, recorded across 262 transactions in the CMS Open Payments database. In 2021, the company paid $1.8M.
Payments were distributed across 3 medical specialties. The top specialty by payment amount is Rheumatology ($155,378 to 2 doctors).
Payment categories include: Consulting ($6,350), Research ($2.5M).